Full clinical overview, indications, dosage references & safety notes.
Drug class:Chelating Agent (Iron)
Main indication:Iron toxicosis / Iron overload
Species:Dog / Cat
Available forms:Injection
Overview
Deferoxamine (Desferal®) is a chelating agent used in dogs and cats primarily for the treatment of acute or chronic iron intoxication. It is administered parenterally and is most effective when initiated early, before iron is widely distributed into tissues.
Due to poor gastrointestinal absorption, deferoxamine is not effective when given orally for iron poisoning and should be administered intravenously or intramuscularly. When given IV, it must be infused slowly to minimize the risk of adverse cardiovascular effects.
Mechanism of Action (MOA): Deferoxamine binds free ferric (Fe³⁺) ions to form ferrioxamine, a stable and water-soluble complex that is excreted primarily in the urine. It chelates iron from storage forms such as ferritin and hemosiderin, but does not remove iron bound to hemoglobin or transferrin.
Indications
Deferoxamine is used in dogs and cats primarily as a chelating agent for the management of iron toxicity. Its use is most effective when initiated early in the course of intoxication.
Acute iron toxicity: Primary indication; used in animals at risk for or showing clinical signs of iron poisoning.
Chronic iron overload: May be used in selected cases to reduce excess iron stores over time.
Severe iron intoxication: Indicated in moderate to severe cases where systemic toxicity is present or serum iron concentrations are elevated.
Early intervention: Most effective when started within 12–24 hours after iron ingestion, before significant tissue distribution occurs.
Dosage (Reference)
Dog
In dogs, deferoxamine is used for treatment of iron toxicity and should be initiated as early as possible (ideally within 12–24 hours of ingestion). Administration may be intravenous or intramuscular depending on clinical setting.
Clinical use
Route
Dose
Frequency
Notes
Severe iron toxicity (preferred method)
IV infusion
Up to 15 mg/kg/hour
q4-8h IM or CRI
Infuse slowly; initiate early (within 12–24 h of ingestion).
Alternative (if IV not feasible)
IM
40 mg/kg every 4–8 hours
q4-8h IM or CRI
Used when IV monitoring is not possible.
Important dosing notes (dogs):
• Continue therapy until serum iron < 300 µg/dL and patient is clinically stable.
• Ideally limit treatment duration to ~24 hours to reduce risk of pulmonary toxicity.
• Rapid IV infusion may cause hypotension or arrhythmias.
• Some clinicians continue treatment until urine clears, but evidence is limited.
• Monitor for delayed GI complications (e.g., strictures) weeks after recovery.
Cat
In cats, deferoxamine dosing is similar to dogs for the treatment of iron toxicity, with route and frequency depending on clinical severity and monitoring capability.
Clinical use
Route
Dose
Notes
Severe iron toxicity (preferred method)
IV infusion
Up to 15 mg/kg/hour
Slow infusion required; early initiation improves outcome.
Alternative (if IV not feasible)
IM
40 mg/kg every 4–8 hours
Use when IV infusion cannot be performed or monitored.
Warnings & Precautions
Deferoxamine should be used with careful monitoring due to its effects on renal function, infection risk, and potential for serious adverse reactions, particularly with inappropriate use or prolonged therapy.
Renal disease: Contraindicated in patients with severe kidney dysfunction or anuria unless dialysis is available, as the drug and its complexes are excreted renally.
Route of administration: Oral administration after iron ingestion is not recommended, as it may increase gastrointestinal iron absorption.
Infection risk: Avoid use in patients with Yersinia infections (e.g., Y. enterocolitica, Y. pseudotuberculosis), as deferoxamine may enhance bacterial growth by acting as an iron carrier.
Fungal infections: Rare but serious infections (e.g., mucormycosis) have been reported; discontinue therapy if suspected.
Pediatric use: Use cautiously in young animals due to potential effects on growth with high doses.
Extravasation risk: Ensure proper administration technique to minimize local tissue irritation and injection site reactions.
Pregnancy: Use only if benefits outweigh risks; skeletal abnormalities have been reported at high doses in animal studies.
Nursing animals: Safety is not established; use with caution.
Monitoring requirements: Requires close monitoring of serum iron levels, renal function, and clinical response during therapy.
Drug Interactions
Clinically relevant interactions with deferoxamine are limited but may affect neurologic status or iron chelation dynamics. Careful monitoring is recommended when used with the following agents.
Prochlorperazine: Concurrent use may cause temporary impairment of consciousness; monitor neurologic status closely.
Vitamin C: May enhance iron removal when used with deferoxamine; however, it may also increase the risk of tissue iron toxicity (especially cardiac), so use cautiously.
Side Effects & Overdose
Side Effects
Adverse effects of deferoxamine in dogs and cats are variable and may involve neurologic, renal, and local injection site reactions. Many effects are dose-dependent or associated with rapid IV administration.
Allergic reactions: May include hypersensitivity responses such as hives or respiratory signs.
Injection site reactions: Pain, swelling, and local irritation may occur with IM or IV administration.
Auditory neurotoxicity: Hearing disturbances may occur, particularly with prolonged or high-dose therapy.
Visual disturbances: Changes in visual acuity have been reported in some cases.
Gastrointestinal effects: May include vomiting, diarrhea, and general GI discomfort.
Renal dysfunction: May occur due to renal excretion of the drug and its complexes.
Urine discoloration: Reddish-brown (“vin rosé”) urine is common and indicates iron excretion; this is harmless.
Rapid IV effects: Fast administration may cause tachycardia, hypotension, convulsions, wheezing, or urticaria.
Respiratory effects: High doses (especially in humans) have been associated with respiratory distress.
Overdose
Overdose or prolonged high-dose therapy with deferoxamine may lead to additional metabolic and hematologic complications. There is no specific antidote, and treatment is supportive.
Hypocalcemia: May occur with prolonged or excessive dosing.
Thrombocytopenia: Reduced platelet counts may develop with long-term high-dose use.
Exaggerated adverse effects: Increased severity of neurologic, cardiovascular, or gastrointestinal signs.
Management: Supportive care is recommended, including monitoring of electrolytes, renal function, and hematologic parameters.
No antidote: Treatment is symptomatic and based on clinical presentation.
Key Notes
Practical clinical insights to guide effective use of deferoxamine in dogs and cats with iron toxicity:
Early intervention is critical: Best outcomes are achieved when therapy is initiated before iron is widely distributed into tissues.
Indicator of efficacy: Change of urine color to reddish-brown (“vin rosé”) reflects active iron chelation and excretion.
Limited chelation scope: Only binds free or stored iron (ferritin/hemosiderin) and does not remove iron bound to hemoglobin or transferrin.
Inpatient use: Typically administered in a hospital setting due to need for continuous monitoring and controlled infusion.
Renal elimination dependency: Effectiveness relies on adequate kidney function for excretion of the iron–drug complex.
Timing vs absorption: Less effective once iron has entered intracellular compartments, emphasizing the importance of early treatment.
Adjunctive role: Often used alongside other supportive treatments (e.g., fluid therapy, GI decontamination) in iron toxicity cases.
VetDose Calculator
Calculate Any Dose Instantly
Use our smart dose calculator to get accurate dosing for 500+ veterinary drugs — adjusted for species, weight, and route.
